Experimental intervention for Antineoplastic Agents

Phase-Based Progress Estimates
Cross Cancer Institute, Edmonton, Canada
Antineoplastic Agents+1 More
Experimental intervention - Other
All Sexes
Eligible conditions

Study Summary

Eating Strategies for Chemotherapy Treatment

See full description

Eligible Conditions

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Antineoplastic Agents

Study Objectives

This trial is evaluating whether Experimental intervention will improve 1 primary outcome and 8 secondary outcomes in patients with Antineoplastic Agents. Measurement will happen over the course of 6 weeks.

6 weeks
treatment-induced toxicity
Baseline and 10 weeks
change in computed tomography-derived muscle mass
change in inflammatory status
change in nutritional status
change in physical performance
change in quality of life
change in strength
change in vitamin D status
tumor response to therapy

Trial Safety

Safety Progress

1 of 3

Other trials for Antineoplastic Agents

Trial Design

3 Treatment Groups

Non-experimental intervention
1 of 3
1 of 3
Experimental intervention
1 of 3
Active Control
Experimental Treatment

This trial requires 37 total participants across 3 different treatment groups

This trial involves 3 different treatments. Experimental Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Experimental intervention
Subjects will add certain foods to what they normally eat.
Non-experimental interventionSubjects will continue eating normally.
ObservationalSubjects will continue eating normally.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 10 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline and 10 weeks for reporting.

Closest Location

Cross Cancer Institute - Edmonton, Canada

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Patients with a newly confirmed diagnosis of non-small cell lung cancer scheduled for first line chemotherapy
Patients with a computed tomography (CT) image, which includes scans of the 3rd lumbar region, taken within 45 days before initiation of chemotherapy
Ability to maintain oral intake
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 / Karnofsky Performance Status between 60-100
Ability to give written, informed consent

Patient Q&A Section

What are the signs of antineoplastic agents?

"The symptoms of all antineoplastic agents are similar, and include fever and chills, malaise, anorexia, gastrointestinal symptoms and headache. The duration of symptoms is most usually five to seven days with the exception of gemcitabine and temorol." - Anonymous Online Contributor

Unverified Answer

What are common treatments for antineoplastic agents?

"Anti-neoplastic agents are frequently prescribed using a variety of chemotherapeutic substances. The use of specific chemotherapy is used to combat the disease in many different cases. This treatment is particularly useful for aggressive types of cancer, such as lymphoma. Many antineoplastic agents are also commonly prescribed to treat various forms of neutropenia, such as chemotherapy-induced. The most common type of antineoplastic agents for cancer treatment is also used in anti-neoplastic agents due to the suppression of growth and tumor cells by cytotoxic substances. Cancer is a common cause of death worldwide and is a major medical issue at present." - Anonymous Online Contributor

Unverified Answer

What causes antineoplastic agents?

"There is evidence that some antineoplastic drugs may affect the reproductive system. However, the mechanisms remain only partially understood. answer: The effect of certain antineoplastic agents and their metabolites on the germ line of an adult may cause a specific type of reproduction failure, and it can be a particular problem with drugs that have mutagenic and genotoxic properties, such as alkylating drugs and topoisomerase 1 activating agents." - Anonymous Online Contributor

Unverified Answer

How many people get antineoplastic agents a year in the United States?

"Antineoplastic agents continue to be used in the U.S. There is no data to support the assertion that, in the U.S., antineoplastic agents are more expensive. The U.S. Antineoplastic Agents Committee (CANC) recommends antineoplastic agents in the treatment of solid tumors. However, given the many treatment options now available and limited toxicity experienced by patients taking antineoplastic agents, the CANC has recommended the continued use of antineoplastic agents and has advised treatment committees to employ a variety of approaches in their decisions concerning the use of drugs in cancer treatment. (https://www.canc." - Anonymous Online Contributor

Unverified Answer

What is antineoplastic agents?

"The treatment of neuroblastoma is based upon antineoplastic agents. The evaluation of patient survival is made after chemotherapy to estimate the benefit of the treatment. However, some neuroblastoma patients do not respond to the chemotherapy treatment. So, some neuroblastoma patients need alternative treatment. A number of alternative therapies are used for treatment of neuroblastoma patients such as acupuncture, traditional Chinese medicine, and vitamin therapy. But there is no good evidence to support these alternative therapy and their effect on prognosis of neuroblastoma patients is undefined." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of experimental intervention?

"Side effects of drugs are unpredictable in healthy patients, and the magnitude and nature of the side effects differ between patients. Clinicians, however, can anticipate side effects and are able to inform patients appropriately. Physicians and pharmacists should keep in mind that a drug treatment may not necessarily be safe and effective. Some patients may not require a new treatment that was being tested for clinical trial. To prevent adverse effects and minimize patient morbidity, it is essential that patients are assessed from a multidisciplinary perspective in clinical trials." - Anonymous Online Contributor

Unverified Answer

Does antineoplastic agents run in families?

"The high incidence of nonresponders among relatives of patients who receive chemotherapy for acute leukemia suggests that some determinants for chemoresistance might be inherited. This would offer the possibility of predicting patient treatment outcome and selecting patients who would benefit from a less intense therapy." - Anonymous Online Contributor

Unverified Answer

Does experimental intervention improve quality of life for those with antineoplastic agents?

"The study showed a clear improvement not only in subjective quality of life but also in objective parameters of physical and mental health after experimental intervention by nurse-help. Data from a recent study are the first evidence of positive effect of nurse-help on some aspects of QoL of patients on chemotherapy. This improvement could be potentially useful because in many cancer patients, adjuvant antineoplastic therapy is often considered a stressor for them. Although QoL scores of the nurses did not differ from those of the patients, their presence could not be an excuse to prevent nurse-help in this specific field." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing antineoplastic agents?

"Anti-neoplastic agents are a common drug in the treatment of patients with CLL and SLL. They are a safe choice for the treatment of patients with CLL because this group of patients have many contraindications for the use of chemotherapy. The most common antineoplastic agents used is fludarabine. It is used in the vast majority of fludarabine-intolerant people, which is approximately 80% of people with CLL and almost 100% of people with SLL. Fludarabine appears to be just as well tolerated as fludarabine-based therapy. [Power](http://www.withpower." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in experimental intervention for therapeutic use?

"Recent advances include the introduction of new methods for measurement and analysis of cerebral metabolic response, a better understanding of mechanisms involved in recovery of normal cognitive function and the development of new methods of treatment of Alzheimer's disease that improve the survival of patients with senile dementia." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating antineoplastic agents?

"The use of monoclonal antibodies targeting tumors has evolved significantly since their introduction in the 1980s. Several drugs are FDA-approved for the treatment of patients with SCLC or [small cell lung cancer](https://www.withpower.com/clinical-trials/small-cell-lung-cancer). However, the efficacy of these agents in metastatic breast cancer is still limited. It can be speculated that the introduction of agents such as bevacizumab, which target some of the same receptor-mediated proteins, may have allowed a more effective treatment of metastatic breast cancer." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Antineoplastic Agents by sharing your contact details with the study coordinator.